Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New painkiller aims to ease Post-Surgery pain without stomach upset

NCT ID NCT07637968

Symptom relief Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a newer painkiller, tegileridine, can control pain after major laparoscopic abdominal surgery as well as the standard drug sufentanil, but with fewer gastrointestinal side effects like nausea or constipation. About 84 adults having elective major abdominal surgery will receive one of the two drugs through a patient-controlled pump after surgery. The main goal is to see if tegileridine provides better gut tolerance while keeping pain scores low.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tegileridine
What this could lead to
If tegileridine works as hoped, it could offer a painkiller option after abdominal surgery that is gentler on the stomach and bowels while still controlling pain effectively.
What could go wrong
This is a small, early-phase trial (84 people) comparing two drugs, so results may not apply to everyone. Tegileridine might not prove better or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 84 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-75 years. * Elective major abdominal surgery as defined above. * Body mass index (BMI) 18-30 kg/m². * American Society of Anesthesiologists (ASA) physical status I to III. * Written informed consent. Exclusion Criteria: * Known hypersensitivity to opioids or any component of the study medications. * Clinically significant hypoxemia, such as oxygen saturation less than 90 percentage, or a history of severe asthma. * Known or suspected gastrointestinal obstruction, including paralytic ileus. * Pregnancy or breastfeeding. * Severe hepatic impairment (Child-Pugh class C). * Severe heart failure (NYHA class III-IV) or unstable arrhythmia. * Neurological or psychiatric disorders that may interfere with pain or sedation assessment (e.g., epilepsy, impaired consciousness, uncontrolled psychiatric illness). * History of chronic pain or long-term use of analgesics/analgesic products. * Current use of sedative-hypnotic medications.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Postoperative pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Postoperative pain

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.